Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01432353 · ClinicalTrials.gov registry record · Phase 1

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
39
Enrollment target
8
Study locations

NCT01432353 is a Phase 1 study of Multiple Myeloma that has completed, run by Genentech. The registered enrollment target is 39 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01432353, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
39 participants
Enrollment target
8
Study locations

Study Summary

This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly. Patients exhibiting acceptable safety and evidence of clinical benefit may receive DFRF4539A for up to 17 cycles. Anticipated time on study treatment is 1 year or until disease progression or unacceptable toxicity occurs.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG DFRF4539A

Study Locations (8)

Florida

  • - Jacksonville
  • - Sarasota

Arizona

  • - Scottsdale

California

  • - Duarte

Illinois

  • - Chicago

Maryland

  • - Bethesda

New York

  • - New York

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2011-09
Est. Completion 2014-04
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01432353

The ClinicalTrials.gov registry entry for NCT01432353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which DFRF4539A is the first listed.

NCT01432353 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT01432353 about?

NCT01432353 is a clinical study titled "A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma". This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly. Patients exhibiting acceptable sa...

What is the current status of trial NCT01432353?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2011-09. Estimated completion is 2014-04.

What conditions does trial NCT01432353 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT01432353?

The interventions under investigation include: DFRF4539A (DRUG).

Who is sponsoring clinical trial NCT01432353?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01432353 being conducted?

This trial has 8 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.